RxDoctor Payments Data

Carrie Hesse

Physician Assistant · Dubuque, IANPI 1841828613

Payments from drug & device makers

$2,274in general payments, 2019–2025

Across 108 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$621
  • Astellas Pharma US Inc$543
  • Pfizer$337
  • Johnson & Johnson$288
  • Medtronic$167
  • Coloplast$118
  • plus $199 from 5 others

What the payments were for

  • Travel & lodging$31714%
  • Food & beverage$1,70575%
  • Education$25211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Axonics, Inc.13$621
Astellas Pharma US Inc24$543
Pfizer29$337
Johnson & Johnson18$288
Medtronic7$167
Coloplast7$118
180 Medical, Inc.3$73
Teleflex LLC3$59
Sumitomo Pharma America, Inc.2$31
Bayer1$19
AbbVie1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,274 in reported general payments places this provider in the 90th percentile of 1,140 physician assistant providers in Iowa.

See all physician assistant providers in Iowa

Medicare billing

Part B allowed, 2024
$20,884
Medicare patients
194
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron338$194,681
GemtesaVibegron44$28,885
Tamsulosin Hcl448$9,679
Oxybutynin Chloride ErOxybutynin Chloride227$4,830
Fesoterodine Fumarate ErFesoterodine Fumarate41$3,369
RapafloSilodosin11$2,827
Solifenacin Succinate83$2,404
Silodosin21$1,975
Alfuzosin Hcl ErAlfuzosin Hcl85$1,941
Finasteride139$1,937
Gentamicin Sulfate26$1,100
NitrofurantoinNitrofurantoin Macrocrystal38$930
Trospium Chloride16$649
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst51$582
Sodium ChlorideSodium Chloride Irrig Solution21$519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$543$194,681338 claims
Sumitomo Pharma America, Inc.Gemtesa$31$28,88544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,140 physician assistant providers in Iowa.

Other physician assistant in Dubuque

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →